@FierceMedDev: Thermo soars after Life Tech deal and dials up its expectations. Story | Follow @FierceMedDev
@VarunSaxena2: Federal court postpones Edwards' block of Medtronic's CoreValve. More | Follow @VarunSaxena2
@EmilyWFierce: Cleveland startup won JDRF support for its rapid-acting insulin analog for Type 1 diabetes. News | Follow @EmilyWFierce
@MichaelGFierce: X-ray-activated nanoparticles release #cancer-killing light deeper into tissue. More from FierceDrugDelivery | Follow @MichaelGFierce
> Illumina's ($ILMN) revenue jumped 27% to $421 million in the first quarter, and net income came in at $60 million, beating a $23 million loss from the same period last year. Results
> Cook Medical has launched its Instinct Endoscopic Hemoclip around the globe, marketing a device designed to stop bleeding in the gastrointestinal tract. News
> Siemens ($SI) won FDA clearance for Somatom Force, a computed tomography imaging device. Release
Biotech News
@FierceBiotech: Shooting for IPO glory, Alder cites trial success with migraine drug. More | Follow @FierceBiotech
@JohnCFierce: Amgen beats a path to the FDA, looking for an early approval of leukemia drug. Story | Follow @JohnCFierce
@DamianFierce: BMY pal Alder hit the mark in a migraine trial, good news on the eve of its IPO. News | Follow @DamianFierce
@EmilyMFierce: TB drug could be basis for class of broad-spectrum treatments. More from VaccinesNewsDaily | Follow @EmilyMFierce
> Kala reels in $22.5M to get its next-gen eye drops into PhIII. News
> Spectrum touts PhII cancer data, plans NDA. Item
> Allergan fashions a poison pill as raiders at Valeant promise to gut R&D. Story
Pharma News
@FiercePharma: Google exec figures pharma could go viral on YouTube--if it tried. More from FiercePharmaMarketing. | Follow @FiercePharma
@TracyStaton: $16B deal for GlaxoSmithKline oncology meds turns Novartis into cancer heavyweight. Story | Follow @TracyStaton
@EricPFierce: Gilead turns in eye-popping results because of huge sales of Sovaldi, $2.3B in Q1 sales for the hep C drug. News | Follow @EricPFierce
@CarlyHFierce: Big Pharma sees danger, not safety, in U.S. FDA's new social media guidance. Article | Follow @CarlyHFierce
> Payer revolt notwithstanding, Gilead's Sovaldi earns crown as fastest drug launch ever. News
> Amgen's $4.5B in Q1 sales lags estimates, thanks to slow-selling Enbrel. More
> Biogen sales leap 50% on blockbuster-level Tecfidera sales. Story
> NICE rejects Roche's hot new breast cancer drug Kadclya, then invites negotiations. Article
Drug Delivery News
> Hydrocarbon double-stapling of peptides a new trick in fight against viruses. Report
> Mylan launches first generic transdermal contraceptive patch. News
> X-ray-activated nanoparticles release cancer-killing light deeper into tissue. Article
> Stanford team finds that nanotubes catch a ride with immune cells to reach tumors. More
> DNA nanocages that act like viruses bypass the immune system to deliver drugs. Story
> ProNAi, with delivery tech licensed from Marina, snags $59.5M for cancer trials. Item
Diagnostics News
> MDxHealth broadens reach of prostate cancer Dx with new U.S. PPO deal. News
> Investors initially respond well to Abbott's diagnostics gains. More
> Cepheid's 2014 Q1 produced Dx sales hikes but also more losses. Report
> UW-Madison team concocts asthma blood Dx that could work before symptoms appear. Story
> KineMed, with IPO in sight, joins global diabetes biomarker research project. Article
Pharma Marketing News
> Google exec figures pharma could go viral on YouTube--if it tried. News
> Big Pharma sees danger, not safety, in FDA's new social media guidance. Story
> It's official: Gilead's Sovaldi zooms past previous records with fastest-ever drug launch. Article
> Allergan sales force key to Valeant chief's plans for post-merger growth. Report
> Doc offices that nix free samples cut way back on branded scripts: JAMA study. More
> Lilly nabs FDA approval for its blockbuster cancer hopeful ramucirumab. Item